earnings
confidence high
sentiment neutral
materiality 0.65
Dyne Therapeutics Q2 net loss $52.3M; advances DYNE-251 and DYNE-101 trials
Dyne Therapeutics, Inc.
2022-Q2 EPS reported
-$1.70
- Net loss of $52.3M ($1.01 per share) vs. $30.0M ($0.58) in Q2 2021; R&D expenses rose to $46.7M from $23.9M.
- Cash, equivalents and marketable securities $291.8M as of June 30, 2022, expected to fund operations into H2 2024.
- FDA lifted clinical hold on DYNE-251 IND for Phase 1/2 MAD trial in DMD patients amenable to exon 51 skipping; dosing expected mid-2022.
- New Zealand cleared clinical trial application for DYNE-101 Phase 1/2 MAD trial in DM1; patient dosing expected mid-2022.
- Presented preclinical data for DYNE-101 at ASGCT showing robust DMPK RNA knockdown in muscle models.